Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- Astellas Licenses Linaclotide from Ironwood
November 23, 2009
- Chuikyo Members Split about How to Respond to GRU WG's Recommendation
November 23, 2009
- Big Changes in Style of Discussions at Chuikyo
November 16, 2009
- Strong Yen Hit Top-Eight Domestic Companies’Performance
November 16, 2009
- Pricing Rule to Be Revised for New Products Containing Existing API: Chuikyo
November 16, 2009
- Half-Year Business Results of Domestic Companies: 2 （１）
November 16, 2009
- Share of Original Drugs Not Decreasing Much in Japan Despite Large Fall in Prices: Korosho Survey
November 16, 2009
- Half-Year Business Results of Domestic Companies: 2 （２）
November 16, 2009
- Korosho Considers Revising Medical Fees to Induce Doctors to Prescribe Fewer Antipsychotics
November 16, 2009
- Deeply Cut Prices of New Drugs to Save Failing Healthcare System: Hodanren
November 16, 2009
- REGULATORY NEWS IN BRIEF
November 16, 2009
- Takeda Ties Up with Amylin for Treatment of Obesity
November 16, 2009
- R&D NEWS IN BRIEF
November 16, 2009
- Pfizer Starts Shipment of New Norvasc OD Tablets
November 16, 2009
- Olmetec Acquires 3rd-Largest Share in ARB Market in Japan
November 16, 2009
- Cut Prices of Off-Patent Original Drugs before Calling for Use of Generics: TMA
November 16, 2009
- DSP Hurries to Build Up Its Own Marketing System for Lurasidone
November 16, 2009
- Premium Prices Needed for Biosimilars: Mr Nagano at Chuikyo
November 16, 2009
- Kyorin Licenses Neramexane for Tinnitus from Merz
November 16, 2009
- Asahi Kasei Kuraray Medical's South Korean Subsidiary Starts Operation
November 16, 2009
ページ
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…